What is the current Price Target for the Neumora Therapeutics stock?

The average Neumora Therapeutics target price is $5.67. This is 567.45% higher than the current stock price. The highest price target is 2,020.14%, the lowest is 17.79%. 6 Analysts have issued a price target Neumora Therapeutics 2026 .

How high will the Neumora Therapeutics stock rise?

No reliable answer can be given as to how high the Neumora Therapeutics stock will rise. The performance of stocks, including the Neumora Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Neumora Therapeutics stock today?

The performance of Neumora Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Neumora Therapeutics stock fall?

The decline in Neumora Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Neumora Therapeutics Forecast, price target & analysts

$0.76

10.07% today

Nasdaq, Apr 04, 07:20 pm CET

ISIN

US6409791000

Symbol

NMRA

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Neumora Therapeutics Target price 2025 - Analyst rating & recommendation

Neumora Therapeutics Classifications & Recommendation:

Buy

33%

Hold

56%

Sell

11%

Neumora Therapeutics Price Target

Target Price	$5.67
Price	$0.85
Potential	567.45% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Neumora Therapeutics 2026 . The average Neumora Therapeutics target price is $5.67. This is 567.45% register free of charge higher than the current stock price. The highest price target is $18.00 2,020.14% register free of charge , the lowest is $1.00 17.79% register free of charge .
	A rating was issued by 9 analysts: 3 Analysts recommend Neumora Therapeutics to buy, 5 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Neumora Therapeutics stock has an average upside potential 2026 of 567.45% register free of charge . Most analysts recommend the Neumora Therapeutics stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.53	-1.31
	2.68%	14.38%
P/E		negative

5 Analysts have issued a Neumora Therapeutics forecast for earnings per share. The average Neumora Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.53	2.68%
2025	$-1.31 14.38% Unlock
2026	$-1.08 17.56% Unlock
2027	$-0.68 37.04% Unlock
2028	$-1.00 47.06% Unlock
2029	$-0.75 25.00% Unlock

Current	-0.56	93.81%
2025	-0.65 16.07% Unlock
2026	-0.79 21.54% Unlock
2027	-1.25 58.23% Unlock
2028	-0.85 32.00% Unlock
2029	-1.14 34.12% Unlock

Neumora Therapeutics...

Current Neumora Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
B of A Securities	Locked ➜ Locked	Locked	Apr 02 2025
Guggenheim	Locked ➜ Locked	Locked	Mar 10 2025
Stifel	Locked ➜ Locked	Locked	Mar 07 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 07 2025
RBC Capital	Locked ➜ Locked	Locked	Mar 04 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 04 2025
Needham	Locked ➜ Locked	Locked	Mar 04 2025

Analyst Rating	Date
Locked B of A Securities: Locked ➜ Locked	Apr 02 2025
Locked Guggenheim: Locked ➜ Locked	Mar 10 2025
Locked Stifel: Locked ➜ Locked	Mar 07 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 07 2025
Locked RBC Capital: Locked ➜ Locked	Mar 04 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 04 2025
Locked Needham: Locked ➜ Locked	Mar 04 2025

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now